CYP2C19*17 affects R-warfarin plasma clearance and warfarin INR/dose ratio in patients on stable warfarin maintenance therapy

A Pharmacogenetic versus a Clinical Algorithm for Warfarin Dosing

(2013) Stephen E. Kimmel et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Randomized Trial of Genotype-Guided Dosing of Warfarin

(2013) Munir Pirmohamed et al.   NEW ENGLAND JOURNAL OF MEDICINE

The pharmacokinetics and pharmacodynamics of single dose (R)- and (S)-warfarin administered separately and together: relationship toVKORC1genotype

(2012) John Maddison et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

The population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical factors

(2011) Steven Lane et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacogenetic warfarin dose refinements remain significantly influenced by genetic factors after one week of therapy

(2011) Petra Lenzini et al.   THROMBOSIS AND HAEMOSTASIS

Variability of INR and its relationship with mortality, stroke, bleeding and hospitalisations in patients with atrial fibrillation

(2011) Marcus Lind et al.   THROMBOSIS RESEARCH

Integration of Genetic, Clinical, and INR Data to Refine Warfarin Dosing

(2010) P Lenzini et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

A Pharmacometric Model Describing the Relationship Between Warfarin Dose and INR Response With Respect to Variations in CYP2C9, VKORC1, and Age

(2010) A-K Hamberg et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations

(2010) Rasmus S. Pedersen et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

The effect of CYP2C19 genotypes on the pharmacokinetics of warfarin enantiomers

(2010) T. Uno et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study

(2009) Andrea L. Jorgensen et al.   Pharmacogenetics and Genomics

The largest prospective warfarin-treated cohort supports genetic forecasting

(2008) M. Wadelius et al.   BLOOD

Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers

(2008) R. Michael Baldwin et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Kinetics of omeprazole and escitalopram in relation to the CYP2C19*17 allele in healthy subjects

(2008) Staffan Ohlsson Rosenborg et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY